Patents by Inventor Sergio A. Quezada

Sergio A. Quezada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210009704
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20210009699
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20200407454
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: February 5, 2020
    Publication date: December 31, 2020
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10745485
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10738125
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION
    Publication number: 20200010554
    Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
    Type: Application
    Filed: March 3, 2018
    Publication date: January 9, 2020
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Pascal Merchiers, Sergio Quezada, Karl Peggs, Frederick Arce Vargas, Isabelle Solomon
  • Method for Treating Cancer
    Publication number: 20200000903
    Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 2, 2020
    Inventors: Nicholas McGranahan, Rachel Rosenthal, Charles Swanton, Karl Peggs, Sergio Quezada
  • NEO-ANTIGEN SPECIFIC T CELLS
    Publication number: 20200000904
    Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 2, 2020
    Inventors: Nicholas McGranahan, Rachel Rosenthal, Charles Swanton, Karl Peggs, Sergio Quezada
  • Combination Immunotherapy For The Treatment of Cancer
    Publication number: 20190352398
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 21, 2019
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20190322752
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 24, 2019
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Blanka Prinz
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20190300613
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 3, 2019
    Inventors: ANNE GOUBIER, BEATRIZ GOYENECHEA CORZO, JOSEPHINE SALIMU, KEVIN MOULDER, PSCAL MERCHIERS, MARK BROWN, SERGIO QUEZADA, JAMES GEOGHEGAN, BIANKA PRINZ
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20190284287
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 19, 2019
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF
    Publication number: 20190170729
    Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.
    Type: Application
    Filed: August 22, 2018
    Publication date: June 6, 2019
    Inventors: Randolph J. NOELLE, Li-Fan Lu, Sergio Quezada, David Gondek
  • ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION
    Publication number: 20190135925
    Abstract: The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyR11b (CD32b).
    Type: Application
    Filed: March 17, 2017
    Publication date: May 9, 2019
    Inventors: Sergio Quezada, Karl Peggs, Fred Vargas
  • Combination immunotherapy for the treatment of cancer
    Patent number: 10167337
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 1, 2019
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Combination Immunotherapy For The Treatment of Cancer
    Publication number: 20180251555
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • "IMMUNE CHECKPOINT INTERVENTION" IN CANCER
    Publication number: 20180251553
    Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.
    Type: Application
    Filed: September 12, 2016
    Publication date: September 6, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Nicholas McGranahan, Rachel Rosenthal, Charles Swanton, Karl Peggs, Sergio Quezada
  • Combination immunotherapy for the treatment of cancer
    Patent number: 10023637
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 17, 2018
    Assignees: Board of Regents, The University of Texas System, Memorial Sloan-Kettering Cancer Center
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • METHOD FOR TREATING CANCER
    Publication number: 20180064793
    Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
    Type: Application
    Filed: April 27, 2016
    Publication date: March 8, 2018
    Inventors: Nicholas Mcgranahan, Rachel Rosenthal, Charles Swanton, Karl Peggs, Sergio Quezada